Research Papers:
Estradiol-ERβ2 signaling axis confers growth and migration of CRPC cells through TMPRSS2-ETV5 gene fusion
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2186 views | HTML 3339 views | ?
Abstract
Hogyoung Kim1, Amrita Datta1, Sudha Talwar1, Sarmad N. Saleem1, Debasis Mondal2 and Asim B. Abdel-Mageed1,2,3
1Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana, 70112, USA
2Department of Pharmacology, Tulane University School of Medicine, New Orleans, Louisiana, 70112, USA
3Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana, 70112, USA
Correspondence to:
Asim B. Abdel-Mageed, email: [email protected]
Keywords: estrogen, ERβ2, TMPRSS2:ETV5, IGF-1R, prostate cancer
Received: September 02, 2015 Accepted: July 26, 2016 Published: August 17, 2016
ABSTRACT
Estrogen receptor beta (ERβ) splice variants are implicated in prostate cancer (PC) progression; however their underlying mechanisms remain elusive. We report that non-canonical activation of estradiol (E2)-ERβ2 signaling axis primes growth, colony-forming ability and migration of the androgen receptor (AR)-null castration-resistant PC (CRPC) cells under androgen-deprived conditions (ADC). The non-classical E2-ERβ2 mediates phosphorylation and activation of Src-IGF-1R complex, which in turn triggers p65-dependent transcriptional upregulation of the androgen-regulated serine protease TMPRSS2:ETV5a/TMPRSS2:ETV5b gene fusions under ADC. siRNA silencing of TMPRSS2 and/or ETV5 suggests that TMPRSS2:ETV5 fusions facilitates the E2-ERβ induced growth and migration effects via NF-κB-dependent induction of cyclin D1 and MMP2 and MMP9 in PC-3 cells. Collectively, our results unravel the functional significance of oncogenic TMPRSS2:ETV5 fusions in mediating growth and migration of E2-ERβ2 signaling axis in CRPC cells. E2-ERβ2 signaling axis may have significant therapeutic and prognostic implications in patients with CRPC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11355